KOL ETF

Company to also provide an update on PLEXI-T™ Phase 1 solid tumor trial Company to also provide an update on PLEXI-T™ Phase 1 solid tumor trial

North Bergen, New Jersey--(Newsfile Corp. - October 29, 2024) - Apollo Biowellness, Inc. (OTC Pink: KOAN) - Evolutionary Biologics is pleased to have Dr. Goldberg as a speaker at EvoBio's webinar on regenerative biologics. With extensive experience in regenerative medicine, Dr. Goldberg will shed light on why Evolutionary Biologics, Inc.'s exosomes lead the way in advancing patient care.

Monocl Conferences equips life science organizations with an intuitive solution to enhance conference planning and KOL engagement Monocl Conferences equips life science organizations with an intuitive solution to enhance conference planning and KOL engagement

Access the transcript here HOUSTON , Oct. 17, 2024 /PRNewswire/ -- Moleculin Biotech, Inc., (Nasdaq: MBRX) ("Moleculin" or the "Company"), a late stage pharmaceutical company with a broad portfolio of drug candidates targeting hard-to-treat tumors and viruses, today announced the transcript from its recently hosted Virtual Acute Myeloid Leukemia KOL event is now available. The transcript is accessible under the Virtual AML KOL event on the Event page under the Investors section of the Company's website (moleculin.com) and on the SEC Filings page.

Webinar to focus on a nephrologist's perspective on the use of FUROSCIX for fluid overload in heart failure and potential use in chronic kidney disease Webinar to focus on a nephrologist's perspective on the use of FUROSCIX for fluid overload in heart failure and potential use in chronic kidney disease

MARSEILLE, France--(BUSINESS WIRE)--Innate Pharma to host KOL scientific symposium on immunotherapy in New York on October 3, 2024.

SAN FRANCISCO, CALIFORNIA, Sept. 24, 2024 (GLOBE NEWSWIRE) -- GT Biopharma, Inc. (the “Company”) (NASDAQ: GTBP), a clinical stage immuno-oncology company focused on developing innovative therapeutics based on the Company's proprietary natural killer (NK) cell engager TriKE® platform, today announced it will host a virtual KOL event on Thursday, October 10, 2024 at 12:00 PM ET. To register, click here.

HENDERSON, Nev. , Sept. 11, 2024 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company, hosted a Key Opinion Leader ("KOL") roundtable in Paris this weekend and brought together some of the world's leading experts in sepsis to explore the potential of using Volition's Nu.Q® NETs technology effectively in clinical practice.

WESTLAKE VILLAGE, Calif., July 22, 2024 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a commercial-stage biopharmaceutical company focused on developing meaningful innovations in immuno-dermatology, today announced that it will host a virtual Key Opinion Leader (KOL) event featuring a leading dermatology and immune-mediated skin disease expert to discuss the unmet need and current treatment landscape for individuals with mild to moderate atopic dermatitis (AD).